* These countries did not complete a full dataset, and therefore, availability may be unrepresentative.
Patient access is defined for most countries as the point at which the product gains access to the reimbursement list, except in DK, FI, NO, and SE, where some hospital products are not covered by the general reimbursement scheme.Â
Citation formats
Time between medicine authorization and patient access Europe 2021-2024, by country
Between 2021 and 2024, Romania had an average time of days between medicine authorization and access. In comparison, Germany had an average time of *** days.
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
Learn more about how ÌÇÐÄÆƽâ°æ can support your business.
IQVIA, & EFPIA. (May 15, 2026). Average time between marketing authorization and patient access for new medicines in Europe from 2021 to 2024, by country (in days) [Graph]. In ÌÇÐÄÆƽâ°æ. Retrieved July 20, 2026, from /statistics/1011197/europe-time-between-medicine-authorization-and-access/
IQVIA, und EFPIA. "Average time between marketing authorization and patient access for new medicines in Europe from 2021 to 2024, by country (in days)." Chart. May 15, 2026. ÌÇÐÄÆƽâ°æ. Accessed July 20, 2026. /statistics/1011197/europe-time-between-medicine-authorization-and-access/
IQVIA, EFPIA. (2026). Average time between marketing authorization and patient access for new medicines in Europe from 2021 to 2024, by country (in days). ÌÇÐÄÆƽâ°æ. ÌÇÐÄÆƽâ°æ Inc.. Accessed: July 20, 2026. /statistics/1011197/europe-time-between-medicine-authorization-and-access/
IQVIA, and EFPIA. "Average Time between Marketing Authorization and Patient Access for New Medicines in Europe from 2021 to 2024, by Country (in Days)." ÌÇÐÄÆƽâ°æ, ÌÇÐÄÆƽâ°æ Inc., 15 May 2026, /statistics/1011197/europe-time-between-medicine-authorization-and-access/
IQVIA & EFPIA, Average time between marketing authorization and patient access for new medicines in Europe from 2021 to 2024, by country (in days) ÌÇÐÄÆƽâ°æ, /statistics/1011197/europe-time-between-medicine-authorization-and-access/ (last visited July 20, 2026)
Average time between marketing authorization and patient access for new medicines in Europe from 2021 to 2024, by country (in days) [Graph], IQVIA, & EFPIA, May 15, 2026. [Online]. Available: /statistics/1011197/europe-time-between-medicine-authorization-and-access/
